Vaxart Inc Stock Today

VXRT Stock  USD 0.60  0.01  1.64%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 85

 
High
 
Low
Very High
Vaxart is selling for under 0.6 as of the 24th of November 2024; that is 1.64 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.59. Vaxart has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Vaxart Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of February 2018
Category
Healthcare
Classification
Health Care
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 227.48 M outstanding shares of which 11.27 M shares are at this time shorted by private and institutional investors with about 11.71 trading days to cover. More on Vaxart Inc

Moving together with Vaxart Stock

  0.84ME 23Andme HoldingPairCorr
  0.82VALN Valneva SE ADRPairCorr
  0.86JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against Vaxart Stock

  0.61MDGL Madrigal PharmaceuticalsPairCorr
  0.5KZR Kezar Life SciencesPairCorr
  0.47RNXT RenovoRxPairCorr
  0.34MLYS Mineralys Therapeutics,PairCorr

Vaxart Stock Highlights

CEO PresidentSteven Lo
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.07630.0804
Notably Down
Slightly volatile
Total Current Liabilities17.6 M13.7 M
Significantly Up
Pretty Stable
Non Current Liabilities Total27.5 M20.3 M
Significantly Up
Slightly volatile
Total Assets150.6 M91.8 M
Way Up
Slightly volatile
Total Current Assets43.3 M45.5 M
Notably Down
Pretty Stable
Debt Levels
Vaxart can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaxart's financial leverage. It provides some insight into what part of Vaxart's total assets is financed by creditors.
Liquidity
Vaxart Inc currently holds 26.51 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Vaxart Inc has a current ratio of 8.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vaxart's use of debt, we should always consider it together with its cash and equity.

Change In Working Capital

(10.31 Million)
Vaxart Inc (VXRT) is traded on NASDAQ Exchange in USA. It is located in 170 Harbor Way, South San Francisco, CA, United States, 94080 and employs 109 people. Vaxart is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 136.49 M. Vaxart Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 227.48 M outstanding shares of which 11.27 M shares are at this time shorted by private and institutional investors with about 11.71 trading days to cover. Vaxart Inc currently holds about 129.55 M in cash with (70.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vaxart Probability Of Bankruptcy
Ownership Allocation
Vaxart Inc shows a total of 227.48 Million outstanding shares. About 81.33 % of Vaxart outstanding shares are held by general public with 0.87 (%) owned by insiders and only 17.8 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vaxart Ownership Details

Vaxart Stock Institutional Holders

InstituionRecorded OnShares
Morgan Stanley - Brokerage Accounts2024-06-30
186.6 K
Bank Of America Corp2024-06-30
166.2 K
Monaco Asset Management2024-09-30
164.3 K
Qube Research & Technologies2024-06-30
163.6 K
Charles Schwab Investment Management Inc2024-09-30
153.5 K
Xtx Topco Ltd2024-09-30
136.5 K
Two Sigma Investments Llc2024-09-30
111.1 K
Simplex Trading, Llc2024-06-30
98.3 K
Group One Trading, Lp2024-06-30
84.4 K
Sio Capital Management, Llc2024-09-30
13.6 M
Vanguard Group Inc2024-09-30
10.1 M
View Vaxart Diagnostics

Vaxart Historical Income Statement

At this time, Vaxart's Depreciation And Amortization is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 95.3 M in 2024, despite the fact that Gross Profit is likely to grow to (57.7 M). View More Fundamentals

Vaxart Stock Against Markets

Vaxart Corporate Management

Sarah KhanVP ResourcesProfile
Rajesh KapoorSenior QualityProfile
Shaily GargSenior ManagementProfile
Brant BiehnSr OperationsProfile
Cezar MBAPres CEOProfile

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.